Nasus Pharma Ltd Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted
Nasus Pharma Ltd (NSRX) reported Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted of $5.80 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-03-25.
Financial Statements › Income Statement › Other Income
us-gaap:NetIncomeLossFromContinuingOperationsAvailableToCommonShareholdersDiluted · last filed 2026-03-25
| Period end | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 6 month | Net Income (Loss) from Continuing Operations Available to Common Shareholders, Diluted 12 month |
|---|---|---|
| 2025-12-31 | $5.80M 20-F · filed 2026-03-25 | |
| 2025-06-30 | -$1.19M 6-K · filed 2025-12-29 | |
| 2024-12-31 | $1.55M 20-F · filed 2026-03-25 | |
| 2024-06-30 | -$885.00K 6-K · filed 2025-12-29 | |
| 2023-12-31 | $1.37M 20-F · filed 2026-03-25 |